<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Intravenous delivery of mesenchymal stem cells (MSCs) prepared from adult bone marrow reduces infarction size and ameliorates functional deficits in rat <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e> models </plain></SENT>
<SENT sid="1" pm="."><plain>Placental growth factor (PlGF) is angiogenic to impaired non-neural tissue </plain></SENT>
<SENT sid="2" pm="."><plain>To test the hypothesis that PlGF contributes to the therapeutic benefits of MSC delivery in <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e>, we compared the efficacy of systemic delivery of human MSCs (hMSCs) and hMSCs transfected with a fibre-mutant F/RGD adenovirus vector with a PlGF gene (PlGF-hMSCs) </plain></SENT>
<SENT sid="3" pm="."><plain>A permanent middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) was induced by intraluminal <z:e sem="disease" ids="C1096458" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">vascular occlusion</z:e> with a microfilament </plain></SENT>
<SENT sid="4" pm="."><plain>hMSCs and PlGF-hMSCs were intravenously injected into the rats 3 h after MCAO </plain></SENT>
<SENT sid="5" pm="."><plain>Lesion size was assessed at 3 and 6 h, and 1, 3, 4 and 7 days using <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> imaging and histology </plain></SENT>
<SENT sid="6" pm="."><plain>Functional outcome was assessed using the limb placement test and the treadmill stress test </plain></SENT>
<SENT sid="7" pm="."><plain>Both hMSCs and PlGF-hMSCs reduced lesion volume, induced <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> and elicited functional improvement compared with the control sham group, but the effect was greater in the PlGF-hMSC group </plain></SENT>
<SENT sid="8" pm="."><plain>Enzyme-linked immunosorbent assay of the infarcted hemisphere revealed an increase in PlGF in both hMSC groups, but a greater increase in the PlGF-hMSC group </plain></SENT>
<SENT sid="9" pm="."><plain>These data support the hypothesis that PlGF contributes to neuroprotection and <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> in <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e>, and cellular delivery of PlGF to the brain can be achieved by intravenous delivery of hMSCs </plain></SENT>
</text></document>